RN Mobile Menu


Rheumatology Network

Beyond Zika: 7 Things Rheumatologists Should Know about Chikungunya

Cleveland Clinic's Leonard Calabrese, D.O., talks with Rheumatology Network about chikungunya, a mosquito-borne viral disease that mimics arthritis. (nechaevkon/Shutterstock.com)

Recent Content


An FDA committee has recommended approval of CT-P13 (Remsima), a biosimilar version of infliximab, for rheumatoid arthritis and other conditions.

Bruce Feinberg, D.O.

"Long term, the degree to which providers and payers embrace biosimilars will depend on value assessments that will necessitate health economic and outcomes research."

Louis Tharp

There must be uninterrupted supply of approved biosimilars and safety should be an utmost concern on all levels, CreakyJoints says.

Kristine Lohr, M.D.

"I remain cautiously optimistic that competition will improve patient access, as I support formal postmarketing surveillance in the form of registries as I welcome CT-P13."


Research points to evidence showing that microorganisms inside our bodies could play a role in the development of arthritis, but it could also be a new therapeutic pathway.

Leonard Calabrese, D.O.

With the spread of Zika virus rating as a "public health emergency" by the World Health Organization, another emerging mosquito-borne illness is worrying rheumatologists: chikungunya.

Eric Morand, M.D., PhD.

Eric Morand, M.D., Ph.D., Director of Rheumatology at Monash Health in Australia, speaks with Rheumatology Network about his recent article in Nature Reviews Rheumatology.

By clicking Accept, you agree to become a member of the UBM Medica Community.